Skip to main content
Premium Trial:

Request an Annual Quote

Spectrum Solutions Saliva Collection Device Granted FDA 510(k) Clearance

NEW YORK – Spectrum Solutions announced on Wednesday that it has received 510(k) Class II medical device clearance from the US Food and Drug Administration for a saliva collection device.

The SDNA Saliva Collection Device is used for microbial nucleic acid storage and stabilization. It employs patented preservation media to keep analytes stable for weeks at ambient temperature, the firm said in a statement, and it maximizes detection at low levels and neutralizes viruses within 10 seconds of collection to mitigate unnecessary viral exposure.

"This 510(k) clearance and certification as an IVD molecular diagnostic device enables physicians, hospitals, researchers, and others to leverage our SDNA Saliva Collection Device in a broad array of FDA-approved and [laboratory-developed] diagnostic testing applications," Spectrum Solutions CEO Stephen Fanning said in a statement.

Salt Lake City-based Spectrum Solutions obtained FDA Emergency Use Authorization for its SDNA-1000 saliva self-collection device in 2020.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.